Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.

Authors: Snehal Patel, Jaye Thompson, Mira Patel, F. Joseph Daugherty, Mothaffar F. Rimawi

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps618

Source: Full article

TPS618